COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might HelpCommentary Published on 2020-04-162022-10-30 Journal: Molecules [Category] COVID-19, SARS, [키워드] 2019-nCoV accelerated ameliorated antimalarial cardiac cardiac effect chiral switch Chirality Chloroquine chloroquine/hydroxychloroquine clinical trial COVID-19 detrimental Developed drug Ebola Efficacy ethical concern Hydroxychloroquine indicated Medicines MERS repositioning repurposing Safety safety profile SARS SARS-CoV-2 [DOI] 10.3390/molecules25081834 PMC 바로가기 [Article Type] Commentary
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?Review article Published on 2020-04-012022-10-05 Journal: Journal of Virus Eradication [Category] 신약개발, 치료법, [키워드] 2019 coronavirus disease adverse event AEs Analysis Antiviral Arm ARMS broad-spectrum antiviral comparator conducted COVID-19 drug Ebola Effect Elevation Evidence examined Favipiravir Follow-up for inclusion gastrointestinal AE Human indicated Influenza limitation oseltamivir pandemic Participants Placebo Potential treatment proportion QTC prolongation representing repurposing Result Safe safety profile serious AE serious AEs shown significantly significantly more Specific statistical teratogenicity tolerable Treatment Trial umifenovir uric acid widespread [DOI] 10.1016/S2055-6640(20)30016-9 [Article Type] Review article
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19Review article Published on 2020-04-012022-10-05 Journal: Journal of Virus Eradication [Category] 신약개발, [키워드] accounted acute infection acute respiratory syndrome adjusted AEs Analysis approved calculate Clinical studies Concentration conducted coronavirus coronavirus disease Course COVID-19 COVID-19 patient database demonstrated dosages dose doses drug drugs EC50 Effects Efficacy Endpoint Evidence for inclusion in vitro India ingredient inhibit initiated margin Metrics nitazoxanide pandemic participant per day pharmacies Placebo Placebo-controlled trials plasma concentration Potential treatment promote raised randomised controlled trial RCT RCTs Replication reported required Research Result review Safe safety profile SARS-CoV-2 searched Serious Adverse Event shown significant difference teratogenic teratogenicity treat Treatment treatments for COVID-19 Trial trials [DOI] 10.1016/S2055-6640(20)30017-0 [Article Type] Review article
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 치료를 위한 하이드록시클로로퀸의 시험관 내 항바이러스 활성 및 최적화된 투여 설계의 예측Major Article Published on 2020-03-092022-09-10 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 비임상, [키워드] activity acute respiratory syndrome coronavirus advance autoimmune conditions breath China Chloroquine Chloroquine phosphate Concentration coronavirus coronavirus 2 Critically ill cytokine Cytokine storm Dosing dosing regimen drug effective Evidence followed by Hydroxychloroquine hydroxychloroquine sulfate immunomodulatory effect in vitro in vitro data inhibit SARS-CoV-2 Loading dose lung maintenance dose malaria mechanism of action occur pharmacokinetic pharmacological phosphate projection reached regimen respiratory Result safety profile SARS-CoV-2 SARS-CoV-2 infected patients SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spread sulfate Support the cytokine storm tolerable treat treating SARS-CoV-2 infection use of hydroxychloroquine Vero cells was tested Wuhan [DOI] 10.1093/cid/ciaa237 PMC 바로가기 [Article Type] Major Article
Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast AsiaArticle Published on 2018-08-272024-08-28 Journal: Med Instrum [Category] 말라리아, [키워드] Clinical efficacy drug combination malaria Prophylaxis safety profile
Infliximab for Crohn’s Disease: More Than 13 Years of Real-world ExperienceIBD Live Published on 2018-03-162024-09-04 Journal: Inflammatory bowel diseases [Category] 대상포진, [키워드] Infusion reaction Real-world evidence safety profile TREAT Registry [DOI] 10.1093/ibd/izx072 PMC 바로가기 [Article Type] IBD Live
Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirusArticle Published on 2017-10-122022-10-29 Journal: Scientific Reports [Category] Coronavirus, [키워드] addition administration Alter Antibody-dependent enhancement antiviral activity Antiviral effect ATPase caused cells cellular coronavirus cytoplasmic disease downstream effective Endosomal acidification exhibit Experimental result Feline infectious peritonitis High-dose highlight in vitro model incurable Infection inhibit inhibitory activity intravenous investigated mechanism mice mutated pathogenic safety profile susceptibility therapeutic potential Treatment Vaccine vacuolar viral disease virus virus replication [DOI] 10.1038/s41598-017-13316-0 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)5가 백신(DTaP5-IPV-Hib)과 혼합 1차 시리즈 일정으로 투여되는 신규 6가 백신(DTaP5-IPV-HB-Hib)의 면역원성 및 안전성Clinical Trial Published on 2017-06-272023-06-19 Journal: Vaccine [Category] B형 간염, 백일해, 파상풍, 폴리오, [키워드] DTaP5-IPV-HB-Hib Mixed schedule Primary series safety profile Vaccine immune response. [DOI] 10.1016/j.vaccine.2017.05.043 [Article Type] Clinical Trial
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trialHIV에 감염된 어린이, 청소년 및 젊은 성인(BREATHER)에 대한 주말 휴무 에파비렌즈 기반 항레트로바이러스 요법: 무작위, 공개, 비열등성, 2/3상 시험Articles Published on 2016-06-202022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 1:1 abortion adherent adverse event African age Antiretroviral therapy ART assigned block BREATHER CD4 cell Cell children clinician computer-generated country CTA Dizziness drug efavirenz eligible participant Eligible participants EudraCT European European Commission event finding FIVE France funding grade 3 gynaecomastia headache HIV-1 ideation inferiority inhibitors Intention intention to treat IQR ISRCTN Kaplan-Meier method less life Lipodystrophy list median median age Medical Research Council men neutropenia non-inferiority non-inferiority margin non-inferiority trial nucleoside occurred offer Open-label participant Patient phase 2/3 trial Primary outcome proportion raised randomisation randomisation list randomised Randomly reached Registered reverse transcriptase RNA safety profile Seven shown spontaneous abortion stratified Suicidal ideation Syncope technology Technology assessment the Kaplan-Meier method therapy Toxicity transaminases transcriptase Trial Viral Viral load virological suppression was done web service [DOI] 10.1016/S2352-3018(16)30054-6 PMC 바로가기 [Article Type] Articles
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusClinical Trial Published on 2010-05-112022-10-06 Journal: Proceedings of the National Academy of Sciences of [Category] 진단, [키워드] acquisition Administered Adult Adults Analysis antibody antiviral activity Antiviral effect assays clinical evidence concentrations decrease different double-blind Effectiveness enrolled exhibiting Factors healthy subject Human increase in independent Infected infected children Infection intranasal mechanism mRNA multiple logistic regression murine model nasal nasal washe nucleocapsid number of infected PCR Placebo placebo-controlled study placebo-controlled trial Proinflammatory cytokine proportion Protein protein expression Randomized recipient recipients representing respiratory syncytial virus RNA RSV RSV infection safety profile saline placebo significantly lower siRNA subjects tested therapeutic Therapeutic approach therapy treat uninfected unique viral culture was measured wild-type [DOI] 10.1073/pnas.0912186107 PMC 바로가기 [Article Type] Clinical Trial